CD103+CD8+ Lymphocytes Characterize the Immune Infiltration in a Case With Pseudoprogression in Squamous NSCLC-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

CD103+CD8+ Lymphocytes Characterize the Immune Infiltration in a Case With Pseudoprogression in Squamous NSCLC

Published:2018-10 Issue:10 Volume:13 Page:e193-e196
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Rocha Pedro,Hardy-Werbin Max,Naranjo Dolores,Taus Álvaro,Rodrigo Maite,Zuccarino Flavio,Roth René,Wood Oliver,Ottensmeier Christian H.,Arriola Edurne

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference5 articles.

1. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria;Wolchok;Clin Cancer Res,2009

2. Caramella C, Tazdait M, Mezquita L, et al. Patterns of progression under anti Pd1/Pdl1 in advanced non–small cell lung cancer (NSCLC) patients allow discriminating pseudo-progression. Presented at the ESMO 2017 Congress in Madrid; September 8-12 2017.

3. Report of two cases of pseudoprogression in patients with non–small cell lung cancer treated with nivolumab-including histological analysis of one case after tumor regression;Tanizaki;Lung Cancer,2016

4. “Pseudoprogression” of pulmonary pleomorphic carcinoma during nivolumab therapy;Ito;J Thorac Oncol,2016

5. Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer;Ganesan;Nat Publ Gr,2018

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. [18F]FDG-PET/CT atypical response patterns to immunotherapy in non-small cell lung cancer patients: long term prognosis assessment and clinical management proposal;European Journal of Nuclear Medicine and Molecular Imaging;2024-06-19

2. Noninvasive radiomic biomarkers for predicting pseudoprogression and hyperprogression in patients with non-small cell lung cancer treated with immune checkpoint inhibition;OncoImmunology;2024-02-07

3. Imaging findings can’t mean everything in the era of immunotherapy: a case report and literature review;Immunotherapy;2024-02

4. Navigating the ICI Combination Treatment Journey: Patterns of Response and Progression to First-Line ICI-Based Combination Treatment in Metastatic Renal Cell Carcinoma;Journal of Clinical Medicine;2024-01-05

5. Cardiothoracic complications of immune checkpoint inhibitors;Clinical Imaging;2023-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3